Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors

Key Points

• The aim is to enhance molecular preselection for pediatric patients receiving tyrosine kinase inhibitors for solid tumors.
• Reviewed current molecular preselection criteria for pediatric tumors
• Analyzed molecular factors influencing treatment response
• Proposed improvements based on findings
• Current criteria identified as insufficient for optimizing treatment
• Highlighted need for better molecular understanding to guide therapy
• Encouraged tailored approaches to improve outcomes